OneCarbon develops 1C-01, a living bacterial supplement engineered to support one-carbon metabolism, the biochemical pathway critical for healthy brain ageing. The product is backed by five peer-reviewed Cambridge studies and includes a companion app for tracking cognitive performance over time. Early pilot testing involved 15 participants aged 50–65.
Funding
Funding not disclosed
Founders
Product
Problem
Age-related cognitive decline is driven in part by the failure of one-carbon metabolism, a biochemical pathway that supplies neurons with the fuel and repair materials they need. This pathway is disrupted by nutrient deficiencies, genetic variants, and ageing itself, leading to mitochondrial dysfunction and neuronal damage. Existing dietary supplements are a blunt tool for supporting this pathway, as they spike and clear quickly and are inefficiently converted by some people.
Solution
OneCarbon has developed 1C-01, a living bacterial strain that continuously produces one-carbon metabolites from within the gut, providing steady support to the one-carbon metabolism pathway. The strain was isolated from a naturally occurring gut bacterium and refined in the laboratory to release these essential metabolites. The product is grounded in five peer-reviewed studies from the University of Cambridge and has been piloted in a small human study. Users take one capsule daily and track their cognitive performance through a companion app that includes baseline and follow-up cognitive assessments.
Target Audience
Primary customers are adults aged 50 and older who are concerned about cognitive decline and are seeking a science-backed, proactive approach to brain health and memory support.
Features
- Living bacterial strain engineered to continuously produce one-carbon metabolites in the gut
- Backed by five peer-reviewed Cambridge studies and a pilot human study with 15 participants aged 50–65
- Companion app with 15-minute cognitive assessments measuring reaction time, memory, and focus
- Longitudinal score tracking to visualize cognitive changes over 4–8 week intervals
- 30-day money-back guarantee with no return of unused capsules required
- Currently undergoing clinical validation through the PROFILE Phase I trial